GLP-1 lawsuits highlight uncertainty over rare serious side effects

NPR examines lawsuits alleging serious eye and digestive injuries linked to GLP-1 drugs. Observational studies and voluntary adverse-event reports cannot by themselves establish causation or how often complications occur. Novo Nordisk and Eli Lilly dispute the claims, and the FDA says it is assessing possible optic-neuropathy risks before deciding whether regulatory action is needed.